Journal of Clinical Oncology· 2013Q1
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
- 3,204citations
- Q1SCImago
- 2013year
Short summary
Afatinib significantly improved progression-free survival (PFS) by 4.2 months (11.1 vs. 6.9 months) compared to cisplatin plus pemetrexed chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine